The existence of this reverse transport was indicated by the appearance of increased tumour marker levels (AFP, PSA) and of the secretory protein autotaxin in the circulation as a result of iRGD administration to mice with HCC or prostate cancer, respectively (Fig. 5d). This evidence concerns the gene ENPP2 and hepatocellular carcinoma.